Therefore, it was our aim in this study to establish the clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance, in direct preparation of a clinical trial using these cells. Here, CSPG4 is linked to melanoma.